Ascendis Pharma A/S (ASND) vs BioNTech (BNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed BioNTech (BNTX) over the past year, gaining 8.8% versus a loss of 10.2%. Over five years, ASND leads with a +42.8% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.93 billion vs $15.03 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | BNTX |
|---|---|---|
| Share price | $228.41 | $95.25 |
| Market cap | $15.03B | $23.93B |
| 1-day change | +1.04% | -0.50% |
| YTD return | +7.11% | +0.05% |
| 1-year return | +8.84% | -10.19% |
| 5-year return | +42.77% | -61.54% |
| P/E ratio (TTM) | 17.32 | — |
| Forward P/E | 21.11 | — |
| EPS (TTM) | $13.19 | $-7.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $282.15 | $124.00 |
| 52-week low | $186.05 | $79.52 |
| Distance from 52-week high | -19.05% | -23.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +33.90% | +21.56% |
| Average volume | 656.21K | 1.16M |
| Shares outstanding | 65.80M | 251.20M |
| Employees | 1,189 | 7,807 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASND has outperformed BNTX by 19.0 percentage points over the past year.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
ASND vs BNTX FAQ
Which is bigger, Ascendis Pharma A/S or BioNTech?
BioNTech (BNTX) is larger, with a market capitalization of $23.93B compared with $15.03B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ASND or BNTX?
ASND returned +8.84% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and BioNTech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ascendis Pharma A/S and Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech.